Clinical Trials
206 trialsNCT07595874 2026-05-27
NEST3
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT03180502 2026-05-26
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT07495124 2026-05-26
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
Phase 2 Not yet recruiting
NCT06959641 2026-05-22
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT05672355 2026-05-20
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Suspended
NCT06038526 2026-05-20
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06860815 2026-05-20
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06863402 2026-05-20
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT04042831 2026-05-15
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT07583810 2026-05-15
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07216404 2026-05-14
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05497804 2026-05-13
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT05541016 2026-05-12
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Mayo Clinic
Phase 2 Recruiting
NCT05557877 2026-05-12
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06738368 2026-05-12
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT07582159 2026-05-12
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07582172 2026-05-12
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05672251 2026-05-11
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT05689021 2026-05-11
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT06525766 2026-05-11
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT07578025 2026-05-11
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05718869 2026-05-08
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07087860 2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT06014827 2026-05-07
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06242834 2026-05-07
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT07226453 2026-05-07
PNOC041
University of California, San Francisco
Phase 2 Recruiting
NCT06617455 2026-05-06
VEnT
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT06784726 2026-05-06
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT07468916 2026-05-06
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03179904 2026-05-05
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06112847 2026-05-05
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07017829 2026-05-05
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05053152 2026-05-04
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT06532279 2026-05-04
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT07037004 2026-05-04
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07565974 2026-05-04
THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia
Mayo Clinic
Phase 2 Not yet recruiting
NCT06224673 2026-05-01
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Not yet recruiting
NCT06151847 2026-04-30
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Completed
NCT06538389 2026-04-30
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT07529483 2026-04-30
ERASE-Chemo
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07557056 2026-04-29
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06434064 2026-04-24
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT07365306 2026-04-24
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT07097363 2026-04-23
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Recruiting
NCT04082520 2026-04-22
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT05507541 2026-04-22
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting